About Autonomix
Autonomix is a publicly listed company based in The Woodlands (United States) founded in 2014 by Robert Schwartz and Landy Toth. It operates as a minimally invasive neural monitoring and treatment devices are developed. Autonomix has raised $8.2 million across 3 funding rounds. The company has 11 employees. Its chief executive is Lori Bisson. Autonomix offers products and services including Nerve Sensing Catheter and Ablation System. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is Autonomix Medical, Inc. Its competitors include Route 92 Medical, ReCor Medical, Ablative Solutions, Brattea and Kona Medical and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Founded in 2014 and based in The Woodlands, United States, Autonomix operates in the neuromodulation sector. Proprietary microchips, hardware, and software are developed by the company for integration into catheters or similar devices. Electrophysiologic signal fidelity is improved, and data analysis is simplified through these technologies. Real-time neural monitoring and treatment solutions are provided for clinical applications in next-generation therapies.
- Headquarters The Woodlands, United States
- Employees 11
- Founders Robert Schwartz, Landy Toth
- Stage Public
- SectorsHealthcare
- Website autonomix.com
- Social LinkedIn X Facebook Instagram
- Legal Name Autonomix Medical, Inc.
- Net Profit-$16.71 M (USD)-46.49as on Mar 31, 2026
- EBITDA-$17.02 M (USD)-49.25as on Mar 31, 2026
- Total Equity Funding$8.2M (USD)
in 3 rounds
- Latest Funding Round$2.4M (USD), Series A
Jun 2023
- Employee Count11
Products & Services of Autonomix
Autonomix offers a comprehensive portfolio of products and services, including Nerve Sensing Catheter and Ablation System.
Detects nerve signals for targeted ablation in pain management procedures.
Ablates overactive nerves to treat chronic pain and related conditions.
Funding Insights of Autonomix
Autonomix has successfully raised a total of $8.2M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.4 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.2M
- Total Rounds 3
- Last Round Series A — $2.4M
- First Round $3.8M
(Aug 2014)
All 3 funding rounds of Autonomix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $2.4M | Series A | – | – | – |
| Apr 2022 | $2M | Series A | – | – | – |
| Aug 2014 | $3.8M | Series A | – | – | – |
People of Autonomix
6 people are tracked at Autonomix (6 in leadership); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Robert Schwartz | Co-Founder | Leadership |
Landy Toth | Co-Founder | Leadership |
Lori Bisson | CEO | Leadership |
Trent Smith | Chief Financial Officer | Leadership |
Jennifer Cook | Chief Business Officer | Leadership |
Shaun Pratt | Director Of Corporate Accounting And Reporting | Leadership |
Complete people profiles for Autonomix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Autonomix
Autonomix is a publicly listed company on the NASDAQ with ticker symbol AMIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Jan 2024
- Listed onNASDAQ: AMIX
- Listed entityAutonomix Medical, Inc.
- Exchange sectorHealth technology
- ISINUS05330T3041
- Share price$3.01 (-2.9% on the day) · 2026-10-13
- Market capitalisation$5.9M
- EPS (diluted, trailing year)$-46.48
- Volume (last session)30,752
Financials of Autonomix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$16.7M | -$17.0M |
| 2024 | – | -$11.4M | -$11.4M |
| 2023 | – | -$15.4M | -$7.4M |
| 2022 | – | -$2.0M | -$2.0M |
| 2021 | – | -$13.3M | -$13.6M |
Detailed financial statements for Autonomix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Autonomix
4 dated milestones of Autonomix across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Autonomix is founded.
- Funding First funding round of $3.8M.
- Funding Latest funding round, Series A, of $2.4M.
- IPO Lists on the stock exchange (IPO).
Competitors of Autonomix
Autonomix has 9 listed competitors in our database, 7 of them funded. They include Route 92 Medical, ReCor Medical, Ablative Solutions, Brattea and Kona Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| route92medical.com | 2015 | San Mateo, United States | $167.15M | 51 | Next-generation products for neurointerventional procedures are developed. | |
| recormedical.com | 2009 | Palo Alto, United States | $15M | 93 | Ultrasound-based renal denervation is applied for hypertension treatment. | |
| ablativesolutions.com | 2011 | Kalamazoo, United States | $293.24M | 24 | A catheter-based renal denervation system for hypertension treatment is developed. | |
| brattea.com | 2013 | Xuhui, China | $15.2M | – | Developer of a medical device for the treatment of hypertension | |
| konamedical.com | 2009 | Issaquah, United States | $73.66M | 39 | Provides ultrasound-based renal denervation solutions for hypertension treatment. | |
| vessixvascular.com | 2003 | Laguna Hills, United States | $27.7M | 10 | Thermoplasty technology for occlusive peripheral vascular diseases is developed. | |
| balt.fr | 1977 | Montmorency, France | – | – | Interventional neuroradiology devices for vascular malformations are developed. | |
| kalosmedical.com | 2015 | Suwon-si, South Korea | – | – | Developer of medical devices for the treatment of hypertension & other chronic diseases | |
| maya-medical.com | 2010 | Campbell, United States | $6.92M | – | Catheter based ablative technology for renal denervation to treat hypertension |
Detailed competitors of Autonomix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Autonomix
The website of Autonomix (autonomix.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 41.7% vs previous month
Top companies in Neurology
10 companies that operate in the same segment as Autonomix (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Autonomix
Complete news archive for Autonomix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Autonomix
Autonomix was founded in 2014.
Autonomix is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Lori Bisson is the current CEO of Autonomix.
Autonomix is a funded company, having raised a total of $8.2M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.8M, raised on Aug 2014.
Autonomix has 11 employees.
Founded in 2014 and based in The Woodlands, United States, Autonomix operates in the neuromodulation sector. Proprietary microchips, hardware, and software are developed by the company for integration into catheters or similar devices. Electrophysiologic signal fidelity is improved, and data analysis is simplified through these technologies. Real-time neural monitoring and treatment solutions are provided for clinical applications in next-generation therapies.
Autonomix's top competitors include ReCor Medical, Route 92 Medical and Ablative Solutions.
Autonomix offers Nerve Sensing Catheter and Ablation System.
Yes, Autonomix is publicly traded on NASDAQ under the ticker symbol AMIX.
Autonomix operates through Autonomix Medical, Inc..